SpyGlass Pharma, Inc.(SGP)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
2-STAR RATING
Consider higher Upturn Star rating
BUY for 13 days
PROFIT SINCE LAST BUY
+0.06% ▲
LAST CLOSE
$32.88
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for SGP

11/13/2026: SGP (2-star) has a low Upturn Star Rating. Not recommended to BUY.

SpyGlass Pharma, Inc. is a late-stage biopharmaceutical company focused on transforming glaucoma care through its proprietary drug-eluting intraocular lens technology. The company's primary strength lies in its innovative, procedure-integrated platform that addresses long-standing patient compliance issues with topical eye drops. While its recent IPO and strategic acquisition of manufacturing capabilities have established a solid foundation, the firm remains in a pre-revenue R&D phase. Key risks include the inherent uncertainty of Phase 3 clinical trials, regulatory approval hurdles, and strong competition from large, well-capitalized medical device incumbents. The stock is best suited for growth-oriented investors capable of managing the high volatility associated with clinical-stage biotechnology developments.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company offers high growth potential tied to the successful development and regulatory approval of its disruptive drug-delivery platform.
Momentum investorMixed fitMomentum depends on clinical trial updates and news cycles; a strong fit while the news flow remains positive and the stock shows relative strength.
Value investorWeak fitAs a pre-revenue biotech firm, the company lacks traditional valuation metrics like earnings or consistent cash flow.
Dividend investorWeak fitThe company does not pay dividends and will likely require years of capital reinvestment before any income potential arises.
Low-risk investorWeak fitClinical-stage biotechnology is inherently high-risk, characterized by volatility related to binary regulatory and clinical trial outcomes.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotech stocks often experience sharp price movements based on trial results and regulatory announcements.
Valuation riskHighValuations are based on future potential, leaving little room for error if clinical milestones are missed.
Competition risk (Ophthalmic device leaders)Medium / highLarge incumbents have established distribution networks and physician relationships that could challenge market adoption.
Business qualityMediumWhile the technology is innovative, the company is still in the process of building its manufacturing and commercial infrastructure.
Dividend incomeLow / noneThe company focuses entirely on R&D and capital preservation, offering no income to investors.
Execution riskMedium / highSuccess requires complex, multi-year Phase 3 clinical trials and successful FDA regulatory filings.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.10B USD
Price to earnings Ratio -
1Y Target Price 46.33
Price to earnings Ratio -
1Y Target Price 46.33
Volume (30-day avg) 99.8K shares
Beta -
52 Weeks Range 17.06 - 39.92
Updated Date 11/14/2026
52 Weeks Range 17.06 - 39.92
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -2.51

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit 14.42%
Avg. Invested days 27
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 5.0
Stock Returns Performance Upturn Returns Performance icon 2.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
SGP receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
SGP has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-36.7%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
SGP's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
SGP's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-36.7%, negative) and free-cash-flow growth (-39.4%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 96.3% and approximately 19.5% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 4.36% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

RA Capital Management, LLC 23.98%
NEA Management Company, LLC 22.10%
Sands Capital Ventures, LLC 7.47%
Samsara BioCapital, LLC 6.31%
BlackRock Inc 2.13%

Unit Economics (Per $1K Revenue)

★★★★★
SGP generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
SGP has a relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Ophthalmic Drug Delivery SystemsThe development and future commercialization of the BIM-IOL and BIM-DRS systems.The company is currently an R&D-stage firm; revenue potential depends on successfully bringing its drug-eluting lens to market.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 875.69M
Price to Sales(TTM) -
Enterprise Value 875.69M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 33.45M
Shares Floating 6.51M
Shares Outstanding 33.45M
Shares Floating 6.51M
Percent Insiders 4.36
Percent Institutions 96.32

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.